TABLE 3.
Treatment ranking probability of sitting SBP in the 12‐week group
| Rank probability of sitting SBP in the 12‐week group | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Ranking | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
| AZL | 0.362780 | 0.226455 | 0.108435 | 0.072845 | 0.047505 | 0.047505 | 0.041880 | 0.061740 | 0.020780 |
| CAN | 0.009890 | 0.038945 | 0.102570 | 0.156230 | 0.184460 | 0.188610 | 0.156995 | 0.156905 | 0.005395 |
| FIM | 0.076415 | 0.163330 | 0.288030 | 0.197060 | 0.133295 | 0.078960 | 0.042235 | 0.020060 | 0.000615 |
| IBR | 0.041930 | 0.097690 | 0.193975 | 0.203735 | 0.174860 | 0.126600 | 0.089695 | 0.069890 | 0.001625 |
| LOS | 0.000280 | 0.004115 | 0.022330 | 0.066245 | 0.138480 | 0.227075 | 0.289925 | 0.245150 | 0.006400 |
| OLM | 0.019345 | 0.075300 | 0.191445 | 0.235380 | 0.202205 | 0.138600 | 0.086815 | 0.048960 | 0.001950 |
| TEL | 0.489065 | 0.392545 | 0.081600 | 0.025630 | 0.008210 | 0.002360 | 0.000515 | 0.000070 | 0.000005 |
| VAL | 0.000095 | 0.001620 | 0.011610 | 0.042840 | 0.100930 | 0.189490 | 0.287730 | 0.357950 | 0.007735 |
| PBO | 0 | 0 | 0.000005 | 0.000035 | 0.000180 | 0.0008 | 0.004210 | 0.039275 | 0.955495 |
Preferred direction = ‐1, AZL, azilsartan; C, candesartan cilexetil; FIM, fimasartan; IBR, irbesartan; LOS, losartan; OLM, omlesartan; PBO, placebo; TEL, telmisartan; and VAL, valsartan. Ranking nearer 1 suggest greater efficacy and each value means the probability that interventions are selected as corresponding ranking.
Bold values indicate the highest rank probabilities in each week group.